Streamline Antibody Humanization with BioPhi on Vecura
BioPhi is now integrated into Vecura, enabling researchers to optimize antibody candidates and assess their human-likeness through a streamlined, user-friendly workflow without the need for complex local infrastructure.
What is BioPhi?
BioPhi is an open-source antibody design platform that streamlines the complex process of antibody humanization. By integrating the Sapiens deep-learning model for sequence optimization with the OASis 9-mer peptide evaluation method, it allows researchers to transform non-human therapeutic candidates into more human-like structures. It is especially useful for antibody discovery teams aiming to minimize immunogenicity risks while maintaining high antigen-binding specificity.
What can users do with BioPhi on Vecura?
With BioPhi on Vecura, users can:
- Humanize Lead Candidates: Automatically refine framework sequences of murine or other non-human antibodies while preserving essential CDRs.
- Perform Humanness Profiling: Utilize the OASis engine to identify and address specific non-human 9-mer peptides that could trigger unwanted immune responses.
- Rank Sequence Panels: Compute Sapiens humanness scores to prioritize lead variants before proceeding to wet-lab validation.
- Access Detailed Diagnostics: Review comprehensive tables and alignment data to understand the structural impact of framework substitutions.
What the output means
The output provides detailed sequence redesigns, humanness scores, and percentile rankings against approved therapeutic panels. Additionally, it offers a granular per-peptide analysis that identifies specific sequence regions requiring attention.
This output should be used to support scientific decision-making. It does not replace experimental validation, as computational humanization must always be followed by binding affinity assays to ensure that function remains intact.
Why this matters
The transition from a candidate antibody to a clinical-grade therapeutic requires a delicate balance between retaining antigen specificity and ensuring human compatibility. Historically, this has required significant manual effort and heavy computational infrastructure to screen large sequence libraries against human repertoires.
By bringing BioPhi to Vecura, researchers can now access these sophisticated tools within a unified, guided workflow. This lowers the barrier to entry, enabling faster iteration and more robust optimization of antibody candidates during the early stages of drug development.
- Developed by: Merck
- Source: Official GitHub Repository
- Reference: mAbs (2022) - BioPhi: a platform for antibody humanization and humanness evaluation
Try BioPhi on Vecura.
Open the model workspace and start evaluating it with your own inputs.